Literature DB >> 14556867

Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting.

Atul Aggarwal1, David J Schneider, Burton E Sobel, Harold L Dauerman.   

Abstract

Patients with diabetes are at increased risk for adverse events after coronary stenting, perhaps reflecting a pro-inflammatory state. To characterize the inflammatory response to coronary stenting in patients with and without diabetes, blood samples were obtained from 75 patients before stenting and 10 minutes, 1 hour, and 24 hours later. C-reactive protein (CRP, microg/ml), interleukin (IL)-6 (pg/ml), IL-1 receptor antagonist (pg/ml), and soluble CD40 ligand (ng/ml) were assayed in each sample by enzyme-linked immunosorbent assay. Concentration changes after stenting were identified by repeated-measures analysis of variance. Multivariate analysis was performed to delineate independent predictors of increased concentrations of inflammation markers. Overall, 88% of patients had acute coronary syndromes; 36% had elevated markers of cardiac injury. The preprocedural concentrations of CRP in those with diabetes were more than twice as high as those in patients without diabetes. Two independent predictors of elevated preprocedural CRP concentrations were diabetes (odds ratio 3.95, 95% confidence interval 1.17 to 13.4) and a cardiac marker-positive acute coronary syndrome (odds ratio 3.70, 95% confidence interval 1.22 to 11.2). Preprocedural concentrations of IL-6, IL-1 receptor antagonist, and soluble CD40 ligand tended to be greater in patients with diabetes. The increase in CRP after stenting was much greater for patients without diabetes compared with that in patients with diabetes such that the apparent intensity of inflammation after 24 hours was similar in those with and without diabetes. Thus, patients with and without diabetes exhibit different inflammatory responses to stenting, reflecting the lower preprocedural inflammation in those without diabetes versus those with diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556867     DOI: 10.1016/s0002-9149(03)00971-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Osteoprotegerin is not associated with angiographic coronary calcification.

Authors:  Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  The co-evolution of our understanding of CD40 and inflammation.

Authors:  D H Wagner
Journal:  Diabetologia       Date:  2009-04-10       Impact factor: 10.122

3.  Increased local cytokine production at culprit superficial femoral artery plaques.

Authors:  Cameron W Donaldson; David J Schneider; Daniel J Bertges; Julie E Adams; Nader Z Elgharib; Enkhtuyaa L Mueller; William Prabhu; Taka Ashikaga; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

4.  Systemic inflammation after drug-eluting stent placement.

Authors:  Prospero B Gogo; David J Schneider; Matthew W Watkins; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

5.  Unprotected left main coronary artery disease after revascularization : effect of diabetes on patient outcomes.

Authors:  X Yu; Y Luo; J He; Y Gao; Y Zhang; X Zhang; C Wu; X Ren; S Lv; F Chen
Journal:  Herz       Date:  2013-10-31       Impact factor: 1.443

Review 6.  Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

Authors:  Louis L Nguyen
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

7.  Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study.

Authors:  Boris Schnorbus; Andreas Daiber; Kerstin Jurk; Silke Warnke; Jochem König; Ulrike Krahn; Karl Lackner; Thomas Munzel; Tommaso Gori
Journal:  BMJ Open       Date:  2014-05-06       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.